
欧洲医用大麻市场预测至 2027 年 - COVID-19 影响和按产品类型(鲜花、浓缩物、片剂、外用软膏、胶囊、饮料和食用品)进行的区域分析;医疗应用(疼痛管理、神经健康管理、心理健康管理等);化合物(四氢大麻酚 (THC) - 主要、大麻二酚 (CBD) - 主要、平衡 THC 和 CBD)和国家/地区
No. of Pages: 170 | Report Code: TIPRE00018766 | Category: Life Sciences
No. of Pages: 170 | Report Code: TIPRE00018766 | Category: Life Sciences
欧洲医用大麻市场预计将从 2021 年的 4.921 亿美元增至 2028 年的 138.010 亿美元。预计 2022 年至 2028 年该市场将以 61.1% 的复合年增长率增长。增长主要归因于大麻药用研究活动的增加以及政府资助和对大麻使用的关注增加等因素。然而,非法使用大麻作为街头毒品可能会阻碍市场增长。
大量国家正在通过医用大麻法律,但政府官员很少鼓励卫生专业人员了解大麻草药。 2016年,多位大麻专家应邀前往马其顿,就大麻在临床实践中的使用对当地卫生服务人员进行培训。该计划在斯科普里举行,得到马其顿卫生部的支持和资助。
大麻为马其顿提供了独特的机会,该国的医疗系统正处于发展阶段和现代化。当地医疗专家现在可以在该国开大麻处方。有鉴于此,马其顿大麻推广者与地方政府合作,制定了医用大麻培训计划,以支持医生及其患者。马其顿医用大麻运动势头迅猛,该地区公众对大麻的看法也发生了巨大变化。该地区医用大麻的革命敦促欧盟委员会和成员国解决给科学研究带来负担的监管、财务和文化障碍,并鼓励他们资助研究。
span>
同样,政府正在拨款加速大麻用于治疗 COVID-19 的研发活动。例如,2020 年 9 月,EXMceuticals Inc. 宣布获得资金,用于专注于具有里程碑意义的 COVID-19 活动的研发。欧盟和葡萄牙政府已拨款约 353,000 美元(302,000 欧元)来支持该公司的 BioBlockCOVID 项目,该项目旨在针对构成 COVID-19 的特定分子创建功能性、天然和创新的杀菌剂配方。预计这些资金将加强研究活动并有助于创新新技术。 因此,由于上述进步,医用大麻市场预计在预测期内将快速增长。
用于医疗用途的医用大麻处方于 2017 年 3 月在德国合法化。德国发现了不同类型的医用大麻产品。德国药店正在向患者出售更多的药用大麻。据德国联邦卫生部统计,销量从2015年前六个月的33.8公斤增加到2016年前六个月的61.8公斤。此外,医用大麻或单一大麻素在不同疾病中的临床研究;正在增加。 Sativex 于 2011 年在德国获得许可,作为治疗中重度多发性硬化症 (MS) 难治性痉挛症状的附加疗法。在德国,Sativex 临床试验证明,Sativex 对于 MS 痉挛患者来说是一种经济有效的治疗选择。
此外,由于随着医用大麻的医疗应用不断增加,2018 年 7 月,德国联邦药品和医疗器械研究所 (BfArM) 允许德国在未来四年内种植 10,400 公斤医用大麻。由于医用大麻种植的增加和政府对医用大麻种植的支持不断增加,推动了医用大麻市场的增长。
疾病中心控制和预防 (CDC)、国家医学图书馆、禁止合作伙伴、国家医用大麻机构 (SAKL) 和 Worldometer 是准备欧洲医用大麻市场报告时提到的主要和次要来源。
Strategic insights for Europe Medical Cannabis involve closely monitoring industry trends, consumer behaviours, and competitor actions to identify opportunities for growth. By leveraging data analytics, businesses can anticipate market shifts and make informed decisions that align with evolving customer needs. Understanding these dynamics helps companies adjust their strategies proactively, enhance customer engagement, and strengthen their competitive edge. Building strong relationships with stakeholders and staying agile in response to changes ensures long-term success in any market.
Report Attribute | Details |
---|---|
Market size in 2021 | US$ 492.1 Million |
Market Size by 2028 | US$ 13,801.0 Million |
Global CAGR (2022 - 2028) | 61.1% |
Historical Data | 2019-2020 |
Forecast period | 2022-2028 |
Segments Covered |
By 产品类型
|
Regions and Countries Covered | 欧洲
|
Market leaders and key company profiles |
The regional scope of Europe Medical Cannabis refers to the geographical area in which a business operates and competes. Understanding regional nuances, such as local consumer preferences, economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved regions or adapting their offerings to meet regional demands. A clear regional focus allows for more effective resource allocation, targeted marketing, and better positioning against local competitors, ultimately driving growth in those specific areas.
The Europe Medical Cannabis Market is valued at US$ 492.1 Million in 2021, it is projected to reach US$ 13,801.0 Million by 2028.
As per our report Europe Medical Cannabis Market, the market size is valued at US$ 492.1 Million in 2021, projecting it to reach US$ 13,801.0 Million by 2028. This translates to a CAGR of approximately 61.1% during the forecast period.
The Europe Medical Cannabis Market report typically cover these key segments-
The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the Europe Medical Cannabis Market report:
The Europe Medical Cannabis Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:
The Europe Medical Cannabis Market report is valuable for diverse stakeholders, including:
Essentially, anyone involved in or considering involvement in the Europe Medical Cannabis Market value chain can benefit from the information contained in a comprehensive market report.